THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Joana Apolónio(Hospital for Sick Children), Pedro Castelo‐Branco(Champalimaud Foundation)
Cited by 15
Related Papers
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
|Nature Genetics|2014|654
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488
Assessing cognitive decline in the aging brain: lessons from rodent and human studies
|npj Aging|2023|160